Neurogene Inc. Files 8-K
Ticker: NGNE · Form: 8-K · Filed: Jun 9, 2025 · CIK: 1404644
Sentiment: neutral
Topics: sec-filing, corporate-update
TL;DR
Neurogene filed an 8-K on 6/9/25. No specific details yet, but it's an SEC update.
AI Summary
Neurogene Inc. filed an 8-K on June 9, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Neoleukin Therapeutics, Inc., is based in New York, NY, and operates in the Pharmaceutical Preparations industry. This filing does not contain specific financial figures or event details beyond its classification.
Why It Matters
This 8-K filing indicates Neurogene Inc. is providing updates to the SEC, which could include significant corporate events or financial reporting, requiring investor attention.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without disclosing specific material events or financial figures, making immediate risk assessment difficult.
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- Neoleukin Therapeutics, Inc. (company) — Former Name
- June 9, 2025 (date) — Date of Report
- 535 W 24th Street, 5th Floor New York, NY 10011 (address) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by Neurogene Inc. in this 8-K filing?
The filing categorizes the event as 'Other Events' but does not specify the nature of these events within the provided text.
What is the significance of filing 'Financial Statements and Exhibits' on this date?
This indicates that Neurogene Inc. is providing updated financial information or exhibits to the SEC, as required by regulations, but the specific content is not detailed here.
When was Neurogene Inc. formerly known as Neoleukin Therapeutics, Inc.?
The filing indicates that the name change from Neoleukin Therapeutics, Inc. to Neurogene Inc. occurred on August 12, 2019.
What is Neurogene Inc.'s primary business sector?
Neurogene Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
What is the address of Neurogene Inc.'s principal executive offices?
The principal executive offices of Neurogene Inc. are located at 535 W 24th Street, 5th Floor, New York, NY 10011.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 9, 2025 regarding Neurogene Inc. (NGNE).